Fluotracen (SKF-28,175) is a tricyclic drug which has both antidepressant and antipsychotic activity.[1][2][3] This profile of effects is similar to that of related agents like amoxapine, loxapine, and trimipramine which may also be used in the treatment of both depression and psychosis.[1] It was believed that such duality would be advantageous in the treatment of schizophrenia, as depression is often comorbid with the disorder and usual antipsychotics often worsen such symptoms.[1] In any case, however, fluotracen was never marketed.[3]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID | |
ChemSpider | |
UNII | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C21H24F3N |
Molar mass | 347.425 g·mol−1 |
3D model (JSmol) | |
|
See also
editReferences
edit- ^ a b c Annual Reports in Medicinal Chemistry: v. 14. Academic Press Inc.,U.S. 1979. ISBN 0-12-040514-8.
- ^ Fowler PJ, Zirkle CL, Macko E, et al. (1977). "Fluotracen: a tricyclic compound with the combined properties of antidepressants and antipsychotics in animals". Arzneimittel-Forschung. 27 (8): 1589–95. PMID 410422.
- ^ a b David J. Triggle (1996). Dictionary of Pharmacological Agents. Boca Raton: Chapman & Hall/CRC. ISBN 0-412-46630-9.